Evidence map›Paper›PMID 26269619›Full record

ArticleJournal of clinical microbiology2015

New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group.

Shamira J Shallom, Natalia S Moura, Kenneth N Olivier, Elizabeth P Sampaio, Steven M Holland, Adrian M Zelazny

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Whole-Genome Sequencing for Predicting Clarithromycin Resistance inAntimicrobial agents and chemotherapy · 2019
    Article
  11. Article
  12. Hydroalcoholic Extract and Ethyl Acetate Fraction ofEvidence-based complementary and alternative medicine : eCAM · 2018
    Article
  13. Frontiers in microbiology · 2018
    Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Shamira J ShallomMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Natalia S MouraMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Kenneth N OlivierCardiovascular and Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, Maryland, USA.
Elizabeth P SampaioLaboratory of Clinical Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Maryland, USA Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.
Steven M HollandLaboratory of Clinical Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Maryland, USA.
Adrian M ZelaznyMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA azelazny@mail.nih.gov.
National Institutes of Health Clinical Center · USNational Heart Lung and Blood Institute · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

Bronchiectasis and chronic airway infectionZIAHL006200 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FENNELLY, KEVIN · 2015 to 2025
$25.1M
Genes And Gene Products As ImmunoadjuvantsZIAAI000647 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.6M
Transgenic Animal Models Of Human Immune DefectsZIAAI000646 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.2M
Identification of Clinically Important Microbes by Genomic and Proteomic MethodsZIACL080012 · CLC · CLINICAL CENTER · PI ZELAZNY, ADRIAN MARCELO · 2009 to 2025
$0k
Molecular and Virulence Traits of Bacteria & Fungi Causing Persistent InfectionsZIACL080013 · CLC · CLINICAL CENTER · PI ZELAZNY, ADRIAN MARCELO · 2009 to 2025
$0k
Intramural NIH HHS
6 · The paper itself

Abstract

Members of the Mycobacterium abscessus group (MAG) cause lung, soft tissue, and disseminated infections. The oral macrolides clarithromycin and azithromycin are commonly used for treatment. MAG can display clarithromycin resistance through the inducible erm(41) gene or via acquired mutations in the rrl (23S rRNA) gene. Strains harboring a truncation or a T28C substitution in erm(41) lose the inducible resistance trait. Phenotypic detection of clarithromycin resistance requires extended incubation (14 days), highlighting the need for faster methods to detect resistance. Two real-time PCR-based assays were developed to assess inducible and acquired clarithromycin resistance and tested on a total of 90 clinical and reference strains. A SYBR green assay was designed to distinguish between a full-length and truncated erm(41) gene by temperature shift in melting curve analysis. Single nucleotide polymorphism (SNP) allele discrimination assays were developed to distinguish T or C at position 28 of erm(41) and 23S rRNA rrl gene mutations at position 2058 and/or 2059. Truncated and full-size erm(41) genes were detected in 21/90 and 69/90 strains, respectively, with 64/69 displaying T at nucleotide position 28 and 5/69 containing C at that position. Fifteen isolates showed rrl mutations conferring clarithromycin resistance, including A2058G (11 isolates), A2058C (3 isolates), and A2059G (1 isolate). Targeted sequencing and phenotypic assessment of resistance concurred with molecular assay results. Interestingly, we also noted cooccurring strains harboring an active erm(41), inactive erm(41), and/or acquired mutational resistance, as well as slowly growing MAG strains and also strains displaying an inducible resistance phenotype within 5 days, long before the recommended 14-day extended incubation.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsBase SequenceClarithromycinDNA, BacterialDrug Resistance, BacterialHumansLung DiseasesMethyltransferasesMicrobial Sensitivity TestsMycobacterium Infections, NontuberculousNontuberculous MycobacteriaPolymorphism, Single NucleotideReal-Time Polymerase Chain ReactionRNA, Ribosomal, 23SSequence Analysis, DNAAnti-Bacterial AgentsBacterial ProteinsClarithromycinDNA, BacterialMethyltransferasesRNA, Ribosomal, 23S

Identifiers

PMID26269619
PMCPMC4609725
OpenAlexW1146149405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.